Trial Profile
Phase II Study of P1101 in Early Myelofibrosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Ropeginterferon alfa-2b (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 28 Aug 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 15 Mar 2023 Planned End Date changed from 1 Dec 2023 to 1 Aug 2024.
- 15 Mar 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Aug 2023.